Cellectis S.A. (NASDAQ:CLLS) Short Interest Update

Cellectis S.A. (NASDAQ:CLLS - Get Free Report) saw a significant decrease in short interest during the month of November. As of November 30th, there was short interest totalling 131,400 shares, a decrease of 6.5% from the November 15th total of 140,500 shares. Based on an average daily trading volume, of 56,100 shares, the days-to-cover ratio is presently 2.3 days.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the stock. Barclays dropped their price target on shares of Cellectis from $7.00 to $5.00 and set an "overweight" rating for the company in a research report on Tuesday, November 5th. StockNews.com started coverage on shares of Cellectis in a report on Sunday. They issued a "sell" rating for the company.

Cellectis Trading Down 2.8 %

NASDAQ:CLLS traded down $0.05 on Monday, reaching $1.71. 55,422 shares of the company's stock were exchanged, compared to its average volume of 51,212. The firm has a market capitalization of $95.05 million, a price-to-earnings ratio of -1.32 and a beta of 3.09. Cellectis has a 52-week low of $1.70 and a 52-week high of $3.77. The company has a quick ratio of 1.78, a current ratio of 1.78 and a debt-to-equity ratio of 0.48. The business has a fifty day moving average of $1.91 and a 200-day moving average of $2.09.

Cellectis (NASDAQ:CLLS - Get Free Report) last announced its earnings results on Monday, November 4th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.03). Cellectis had a negative return on equity of 74.55% and a negative net margin of 234.39%. The business had revenue of $18.05 million for the quarter, compared to analysts' expectations of $5.00 million. During the same period in the previous year, the company earned ($0.31) earnings per share. As a group, analysts expect that Cellectis will post -0.46 earnings per share for the current year.

Institutional Trading of Cellectis

Several hedge funds have recently modified their holdings of the stock. Principal Financial Group Inc. increased its holdings in Cellectis by 2.9% during the 2nd quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company's stock worth $817,000 after purchasing an additional 12,467 shares during the period. XTX Topco Ltd acquired a new position in shares of Cellectis during the second quarter worth about $29,000. Long Focus Capital Management LLC increased its stake in shares of Cellectis by 2.9% during the second quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company's stock worth $8,634,000 after buying an additional 130,000 shares during the period. Finally, First Affirmative Financial Network acquired a new stake in Cellectis in the third quarter valued at approximately $45,000. 63.90% of the stock is currently owned by institutional investors and hedge funds.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.